Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Meta10-19 in r/r B-ALL
NCT05747157Phase 1Unknown
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Feb 2023
- Primary completion
- Feb 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Meta10-19 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by The First Affiliated Hospital of USTC. Primary endpoints: Maximum Tolerated Dose at 28 days and Objective Response Rate at 3 months. Status: unknown.
02
Drugs
Meta10-19
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT05747157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05747157.